Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Synergy Pharma Cmn (SGYP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,211,090
  • Shares Outstanding, K 179,950
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,500 K
  • 36-Month Beta 893.41
  • Price/Sales N/A
  • Price/Book 100.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.68 +39.53%
on 12/22/16
6.97 -6.31%
on 01/05/17
+1.36 (+26.31%)
since 12/16/16
3-Month
4.02 +62.44%
on 11/04/16
6.97 -6.31%
on 01/05/17
+1.24 (+23.44%)
since 10/18/16
52-Week
2.50 +161.20%
on 03/23/16
6.97 -6.31%
on 01/05/17
+2.50 (+62.03%)
since 01/15/16

Most Recent Stories

More News
Key FDA Events to Watch Out for in Q1

Two important regulatory events scheduled in the first quarter of 2017.

Zacks.com featured highlights: Beazer Homes USA, EnerSys, Greenhill, Synergy Pharmaceuticals and Movado Group

Zacks.com featured highlights: Beazer Homes USA, EnerSys, Greenhill, Synergy Pharmaceuticals and Movado Group

5 Stocks to Play on New Analyst Coverage

As analysts are one of the most important information intermediaries in capital markets, initiation of coverage by them creates value for companies. So, it???s a good strategy to bet on stocks that have...

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Two Key FDA Decisions to Watch Out for in January 2017

Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold

Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.

Synergy Reports Positive Top-Line Phase III Data on IBS Drug

Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients...

Lockheed Martin and Cintas drop; Fred's and Cal-Maine climb

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:

Synergy Pharmaceuticals Announces Positive Results in Second Phase 3 Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide,...

Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) to Ring The Nasdaq Stock Market Closing Bell

What:

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-...

See More

Support & Resistance

2nd Resistance Point 6.70
1st Resistance Point 6.62
Last Price 6.53
1st Support Level 6.44
2nd Support Level 6.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.